Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  vandetanib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 55 for your search:
Start Over
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00097, 2011-004701-24, NCT01496313
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and older
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00032, 6474IL/0032, NCT00312377
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00057, EUDRACT No. 2006-000259-16, NCT00364351
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00058, NCT00410761
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00044, EUDRACT Number 2006-002384-12, NCT00404924
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00036, EUDRACT No. 2006-003695-35, NCT00418886
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00088, 2010-023428-26, NCT01298323
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4203C00011, 2013-000422-58, NCT01876784
Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0063, NCI-P6680, NCT00293566
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-377, IRUSZACT0018, NCT00441142
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 5 to 18
Sponsor: NCI
Protocol IDs: 070189, 07-C-0189, NCI-07-C-0189, NCT00514046
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00098, NCT01661179
Phase II Study of ZD6474 in Patients With Relapsed Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-IND145, ZENECA-6474IL/0004, IND145
Phase II Randomized Study of ZD6474 Versus Gefitinib (ZD1839) in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Who Failed Prior First-Line Platinum-Based Chemotherapy
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-03090, ZENECA-6474IL/0003, NCT00059722
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00008, NCT00098345
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00068, NCT00358956
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0825, NCT00410189
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00048, NCT00454116
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-283, NCT00459043
Malignant Pleural Effusion With ZD6474
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0929, NCI-2012-02082, W81XWH-05-2-0027, NCT00402896
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00047, NCT00500292
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 20 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00072, NCT00508001
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00079, NCT00537095
Start Over